Month: March 2022

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《High Grade Serous Ovarian Carcinoma in a Liver Transplant Recipient Patient: A Case Report and Review of Literature.》. Authors are Tokalioglu, Abdurrahman Alp; Ozgun, Yigit Mehmet; Celik, Fatih; Akdogan, Meral; Bostanci, Erdal Birol; Turan, Taner; Turkmen, Osman.The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).Category: esters-buliding-blocks. Through the article, more information about this compound (cas:41575-94-4) is conveyed.

According to GLOBOCAN 2020 data, the incidence of ovarian cancer is 1.6%. Ovarian cancer ranks 19th in incidence and 15th in mortality with a rate of 2.1%. High-grade serous ovarian cancer is the most common subtype of malignant ovarian tumors, and around 70% to 80% of all ovarian malignancies are included in this group. The incidence of gynecologic malignancies in liver transplant recipients is between 0% and 1.5%, and the duration of diagnosis for gynecologic cancer after transplantation is between 1 and 59 months. A 52-year-old patient was admitted to our hospital complaining of a periumbilical nodule. Her medical history revealed she had a cadaver liver transplantation in 2003 because of cirrhosis due to hepatitis B. On her physical examination, an erythematous nodular lesion was observed in the umbilical region. Ultrasonography demonstrated diffuse ascites and approximately 30 mm of a soft tissue density with lobulated contours located on the periumbilical skin. Both cytology and biopsy results were reported consistent with high-grade serous ovarian cancer. She underwent an operation, she had no problems during the postoperative follow-ups, and she was discharged on the eighth postoperative day. According to the 2018 International Federation of Gynecology and Obstetrics staging criteria for ovarian cancer, the patient’s cancer was stage IVB. The patient received 6 cycles of adjuvant chemotherapy that included carboplatin (AUC = 6) and paclitaxel (175 mg/m2). The patient was evaluated as having a complete response according to Response Evaluation Criteria in Solid Tumors. The patient has been disease-free for 11 months after diagnosis.

There is still a lot of research devoted to this compound(SMILES：O=C1C2(CCC2)C(O[Pt]O1)=O.N.N)Category: esters-buliding-blocks, and with the development of science, more effects of this compound(41575-94-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Benetis, N.; Kowalewski, J.; Nordenskioeld, L.; Edlund, U. published the article 《Nuclear spin relaxation in a paramagnetic nickel(II) complex. An experimental test of new theoretical models》. Keywords: nuclear spin relaxation methylheptanedionato nickel.They researched the compound: Bis(2,2,6,6-tetramethyl-3,5-heptanedionato)nickel(II)( cas:14481-08-4 ).Related Products of 14481-08-4. Aromatic heterocyclic compounds can be divided into two categories: single heterocyclic and fused heterocyclic. In addition, there is a lot of other information about this compound (cas:14481-08-4) here.

Paramagnetic relaxation enhancement data are reported for 15N and 1H in aniline in the presence of bis(2,2,6,6-tetramethylheptanedionato)nickel(II). For 15N, the spin-lattice T1 as well as spin-spin relaxation rates are reported at 2.35 and 5.875 T and of 244-356 K. For 1H T1 data at 2 fields (5.875 and 9.4 T) 263-333 K. The exptl. data are fitted to a new theor. model, not invoking the concept of electron spin relaxation times, which is valid in the slow motion regime for the electron spin. The parameters obtained form a consistent set and have reasonable values, but the 15N results could not be fitted by using the conventional model based on the modified Solomon-Bloembergen equations.

There is still a lot of research devoted to this compound(SMILES：CC(C)(C1=O[Ni+2]2(O=C(C(C)(C)C)[CH-]1)O=C([CH-]C(C(C)(C)C)=O2)C(C)(C)C)C)Related Products of 14481-08-4, and with the development of science, more effects of this compound(14481-08-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Zharkova, G. I.; Baidina, I. A.; Stabnikov, P. A. published an article about the compound: Bis(2,2,6,6-tetramethyl-3,5-heptanedionato)nickel(II)( cas:14481-08-4,SMILESS:CC(C)(C1=O[Ni+2]2(O=C(C(C)(C)C)[CH-]1)O=C([CH-]C(C(C)(C)C)=O2)C(C)(C)C)C ).Reference of Bis(2,2,6,6-tetramethyl-3,5-heptanedionato)nickel(II). Aromatic heterocyclic compounds can be classified according to the number of heteroatoms or the size of the ring. The authors also want to convey more information about this compound (cas:14481-08-4) through the article.

New volatile β-iminoketonate complexes of Ni(L)2 and Pd(L)2 were obtained, where HL is β-Aminovinylketone, CMe3C(NH2):CHC(O)CMe3, 2,2,6,6-tetramethyl-3-amino-4-hepten-5-one. Synthesis of the compound is described, and element anal., DTA, and IR spectral data are given. The complexes were studied by XRPA and XRD. The structures are mol., consist of the trans complexes, and are isostructural. The central atoms have a square plane environment with a (MO2N2) coordination unit. The M-O and M-N distances and the N-M-O valence chelate angles are equal, 1.834 Å, 1.848 Å, and 94.2° for Ni(L)2 and 1.972 Å, 1.975 Å, and 92.4° for Pd(L)2.

There is still a lot of research devoted to this compound(SMILES：CC(C)(C1=O[Ni+2]2(O=C(C(C)(C)C)[CH-]1)O=C([CH-]C(C(C)(C)C)=O2)C(C)(C)C)C)Reference of Bis(2,2,6,6-tetramethyl-3,5-heptanedionato)nickel(II), and with the development of science, more effects of this compound(14481-08-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)(SMILESS: O=C1C2(CCC2)C(O[Pt]O1)=O.N.N,cas:41575-94-4) is researched.Synthetic Route of C36H30NO2P. The article 《First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma》 in relation to this compound, is published in Cancer Immunology Immunotherapy. Let’s take a look at the latest research on this compound (cas:41575-94-4).

Budigalimab is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death protein 1 (PD-1). We present the safety, efficacy, pharmacokinetic (PK), and pharmacodynamic data from patients enrolled in the head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) expansion cohorts of the phase 1 first-in-human study of budigalimab monotherapy (NCT03000257; registered 15 Dec. 2016). Patients with recurrent/metastatic HNSCC or locally advanced/metastatic NSCLC naive to PD-1/PD-1-ligand inhibitors were enrolled; patients were not selected on the basis of oncogene driver mutations or PD-L1 status. Budigalimab was administered at 250 mg i.v. Q2W or 500 mg i.v. Q4W until disease progression/unacceptable toxicity. The primary endpoints were safety and PK; the secondary endpoint was efficacy. Exploratory endpoints included biomarker assessments. In total, 81 patients were enrolled (HNSCC: N = 41 [PD-L1 pos.: n = 19]; NSCLC: N = 40 [PD-L1 pos.: n = 16]); median treatment duration was 72 days (range, 1-617) and 71 days (range, 1-490) for the HNSCC and NSCLC cohorts, resp. The most frequent grade ≥ 3 treatment-emergent adverse event was anemia (HNSCC: n = 9, 22%; NSCLC: n = 5, 13%). Both dosing regimens had comparable drug exposure and increased interferon gamma-induced chemokines, monokine induced by gamma interferon, and interferon-gamma-inducible protein 10. Objective response rates were 13% (90% CI, 5.1-24.5) in the HNSCC cohort and 19% (90% CI, 9.2-32.6) in the NSCLC cohort. Median progression-free survival was 3.6 mo (95% CI, 1.7-4.7) and 1.9 mo (95% CI, 1.7-3.7) in the HNSCC and NSCLC cohorts. The safety, efficacy and biomarker profiles of budigalimab are similar to other PD-1 inhibitors. Development of budigalimab in combination with novel anticancer agents is ongoing.

There is still a lot of research devoted to this compound(SMILES：O=C1C2(CCC2)C(O[Pt]O1)=O.N.N)Formula: C6H12N2O4Pt, and with the development of science, more effects of this compound(41575-94-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Most of the natural products isolated at present are heterocyclic compounds, so heterocyclic compounds occupy an important position in the research of organic chemistry. A compound: 415918-91-1, is researched, SMILESS is C[C@@H](N(P1OC2=CC=C3C=CC=CC3=C2C4=C5C=CC=CC5=CC=C4O1)[C@@H](C6=CC=CC=C6)C)C7=CC=CC=C7, Molecular C36H30NO2PJournal, Article, Organic & Biomolecular Chemistry called Application of iridium catalyzed allylic substitution reactions in the synthesis of branched tryptamines and homologues via tandem hydroformylation-Fischer indole synthesis, Author is Bondzic, Bojan P.; Farwick, Andreas; Liebich, Jens; Eilbracht, Peter, the main research direction is tryptamine preparation allylic substitution iridium catalyst; hydroformylation Fischer indole synthesis iridium allylic substitution.Synthetic Route of C36H30NO2P.

Combination of enantioselective allylation reactions with a tandem hydroformylation-Fischer indole synthesis sequence as a highly diversity-oriented strategy for the synthesis of tryptamines and homologues was explored. This modular approach allows the substituents at C3 of the indole core, the type of the amine moiety, and the distance of the amine moiety to the indole core in the final synthetic step to be defined. The starting materials required for the hydroformylation step were synthesized via iridium catalyzed enantioselective allylic substitution reactions in high yields and excellent enantioselectivities. The Rh catalyzed hydroformylation step in the presence of Ph hydrazine, allows the in situ formed aldehyde to be trapped as the hydrazone. Subsequent acid catalyzed indolization furnishes the desired indole structures, e.g. I, in moderate to good yields.

There is still a lot of research devoted to this compound(SMILES：C[C@@H](N(P1OC2=CC=C3C=CC=CC3=C2C4=C5C=CC=CC5=CC=C4O1)[C@@H](C6=CC=CC=C6)C)C7=CC=CC=C7)Synthetic Route of C36H30NO2P, and with the development of science, more effects of this compound(415918-91-1) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

In general, if the atoms that make up the ring contain heteroatoms, such rings become heterocycles, and organic compounds containing heterocycles are called heterocyclic compounds. An article called Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma, published in 2022-02-28, which mentions a compound: 41575-94-4, Name is cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), Molecular C6H12N2O4Pt, Computed Properties of C6H12N2O4Pt.

Eye-preserving therapy in retinoblastoma comprises systemic chemotherapy, but studies analyzing the efficacy of different chemotherapy regimens are scarce. The efficacy and side effects of two different eye-preserving chemotherapy regimens containing either vincristine, etoposide, and carboplatin (VEC) or cyclophosphamide, vincristine, etoposide, and carboplatin (CyVEC) were compared in a prospective non-interventional observational study including children diagnosed with retinoblastoma between 2013 and 2019 in Germany and Austria. Event-free eye survival (EFES) and overall eye survival (OES) of all 164 eyes treated with both regimens and risk factors were investigated. The EFES after VEC (2-yr EFES 72.3) was higher than after CyVEC (2-yr EFES 50.4) (plogrank < .001). The OES did not differ significantly between the two treatment groups (plogrank = .77; 2-yr OES VEC: 82.1vs. CyVEC: 84.8). Advanced International Classification of Retinoblastoma (ICRB) group was prognostic for a lower EFES (plogrank < .0001; 2-yr EFES ICRB A/B/C 71.3vs. ICRB D/E 43.0) and OES (plogrank < .0001; 2-yr OES ICRB A/B/C 93.1vs. ICRB D/E 61.5). The multivariate anal. showed that age at diagnosis older than 12 mo and ICRB A/B/C were associated with better EFES. No second malignancies or ototoxicities were reported after a follow-up of median 3.1 years after diagnosis of retinoblastoma (range 0.1-6.9 years). Despite omitting cyclophosphamide, the EFES was higher after VEC chemotherapy that contains higher doses of carboplatin compared to CyVEC. The major risk factor for enucleation was advanced ICRB tumor grouping. Randomized clin. trials on efficacy and side effects of eye-preserving chemotherapy are required to tailor treatment protocols for retinoblastoma patients. There is still a lot of research devoted to this compound(SMILES：O=C1C2(CCC2)C(O[Pt]O1)=O.N.N)Computed Properties of C6H12N2O4Pt, and with the development of science, more effects of this compound(41575-94-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Most of the compounds have physiologically active properties, and their biological properties are often attributed to the heteroatoms contained in their molecules, and most of these heteroatoms also appear in cyclic structures. A Journal, Article, Chemical Communications (Cambridge, United Kingdom) called Supertetrahedral decametallic Ni(II) clusters directed by μ6-tris-alkoxides, Author is Shaw, Rachel; Tidmarsh, Ian S.; Laye, Rebecca H.; Breeze, Barbara; Helliwell, Madeleine; Brechin, Euan K.; Heath, Sarah L.; Murrie, Mark; Ochsenbein, Stefan; Guedel, Hans-Ulrich; McInnes, Eric J. L., which mentions a compound: 14481-08-4, SMILESS is CC(C)(C1=O[Ni+2]2(O=C(C(C)(C)C)[CH-]1)O=C([CH-]C(C(C)(C)C)=O2)C(C)(C)C)C, Molecular C22H38NiO4, Application of 14481-08-4.

The authors report the syntheses, structures and magnetic properties of two decametallic Ni(II) clusters with unprecedented supertetrahedral cores, stabilized by the (hitherto unobserved) μ6-coordination modes of the tris-alkoxides {MeC(CH2O)3}3- and {C6H9O3}3-, namely [Ni10O(thme)4(dbm)4(O2CPh)2(EtOH)6] (I) and [Ni10O(cht)4(dpm)4(OAc)2(H2O)2] (II) (H3thme = 1,1,1-tris(hydroxymethyl)ethane; H3cht = cis,cis-1,3,5-cyclohexanetriol; Hdbm = dibenzoylmethane; Hdpm = dipivaloylmethane). The crystal structures of I and II were determined I exhibits antiferromagnetic exchange.

There is still a lot of research devoted to this compound(SMILES：CC(C)(C1=O[Ni+2]2(O=C(C(C)(C)C)[CH-]1)O=C([CH-]C(C(C)(C)C)=O2)C(C)(C)C)C)Application of 14481-08-4, and with the development of science, more effects of this compound(14481-08-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Quality Control of (11bR)-N,N-Bis[(1R)-1-phenylethyl]dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine. The fused heterocycle is formed by combining a benzene ring with a single heterocycle, or two or more single heterocycles. Compound: (11bR)-N,N-Bis[(1R)-1-phenylethyl]dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine, is researched, Molecular C36H30NO2P, CAS is 415918-91-1, about Influence of copper salts, solvents, and ligands on the structures of precatalytic phosphoramidite copper complexes for conjugate addition reactions. Author is Zhang, Hongxia; Gschwind, Ruth M..

For Cu-catalyzed enantioselective conjugate addition reactions of organozinc reagents, the available knowledge about the mechanism and the structures involved is still insufficient to understand in detail the strong influences of solvent, salt, and ligand size, or to enable a rational control of this reaction. Screening with three phosphoramidite ligands and four Cu(I) salts using NMR spectroscopy revealed a binuclear Cu complex with mixed trigonal/tetrahedral stereochem. as the basic structural motif of the ground state of precatalysts with highly stereoselective ligands. Ligands with smaller amine moieties allow higher coordination numbers and higher aggregation levels, leading to reduced ee values. Since the ESI mass spectra of several precatalytic Cu halide complexes show a striking correlation with the structures observed in solution, ESI-MS may be used as a fast tool to determine the maximum number of phosphoramidite ligands attached to Cu.

There is still a lot of research devoted to this compound(SMILES：C[C@@H](N(P1OC2=CC=C3C=CC=CC3=C2C4=C5C=CC=CC5=CC=C4O1)[C@@H](C6=CC=CC=C6)C)C7=CC=CC=C7)Quality Control of (11bR)-N,N-Bis[(1R)-1-phenylethyl]dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine, and with the development of science, more effects of this compound(415918-91-1) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Electric Literature of C36H29O4P. Aromatic heterocyclic compounds can also be classified according to the number of heteroatoms contained in the heterocycle: single heteroatom, two heteroatoms, three heteroatoms and four heteroatoms. Compound: (11bR)-2,6-Bis(3,5-dimethylphenyl)-4-hydroxydinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepine 4-oxide, is researched, Molecular C36H29O4P, CAS is 861909-53-7, about Site-Selective Acylation of Natural Products with BINOL-Derived Phosphoric Acids. Author is Li, Junqi; Grosslight, Samantha; Miller, Scott J.; Sigman, Matthew S.; Toste, F. Dean.

The site-selective acylation of a steroidal natural product 19-hydroxydehydroepiandrosterone catalyzed by 1,1′-Bi(2-naphthol)-derived (BINOL) chiral phosphoric acids (CPAs) is described. Systematic variation and multivariate linear regression anal. reveal that the same steric parameters typically needed for high enantioselectivity with this class of CPAs are also required for site-selectivity in this case. D. functional theory calculations identify addnl. weak CH-π interactions as contributors to site discrimination. We further report a rare example of site-selective acylation of phenols through the evaluation of naringenin, a flavonoid natural product, using CPA catalysis. These results suggest that BINOL-derived CPAs may have broader applications in site-selective catalysis.

If you want to learn more about this compound((11bR)-2,6-Bis(3,5-dimethylphenyl)-4-hydroxydinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepine 4-oxide)Electric Literature of C36H29O4P, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(861909-53-7).

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Electronic structure and molecular association of some bis-(β-diketone)-nickel(II) complexes》. Authors are Fackler, J. P. Jr.; Cotton, F. A..The article about the compound:Bis(2,2,6,6-tetramethyl-3,5-heptanedionato)nickel(II)cas:14481-08-4,SMILESS:CC(C)(C1=O[Ni+2]2(O=C(C(C)(C)C)[CH-]1)O=C([CH-]C(C(C)(C)C)=O2)C(C)(C)C)C).Computed Properties of C22H38NiO4. Through the article, more information about this compound (cas:14481-08-4) is conveyed.

Bis-(2,2,6,6-tetramethyl-3,5-heptanedione)-Ni(II) (I) is diamagnetic. Hydrocarbon solutions of I are red and have an absorption maximum at 535 mμ with a mol. extinction coefficient of 60. I forms a blue-green paramagnetic dihydrate. Bis(2,2-dimethyl-3,5-heptanedione)-Ni(II) (II) is paramagnetic, μeff. (297.4°K.) = 3.41 Bohr magnetons in the solid phase. Solutions of II in toluene have magnetic moments that are concentration and temperature dependent. The color of solutions of II changes from green near 0° to red at 50°, corresponding to an increase in absorption at 535 mμ. The paramagnetism in anhydrous β-diketone complexes of Ni(II) may be attributed to intermol. interactions, the monomers being diamagnetic. Thus the bulky tert-Bu groups in I prevent intermol. reactions and so anhydrous I is diamagnetic. In II interactions can take place and II is paramagnetic. Anhydrous bis-(3-phenyl-2,4-pentanedione)-Ni(II) (III) also is diamagnetic. Here the Ph group hinders interaction. III behaves similarly to II in toluene solution

If you want to learn more about this compound(Bis(2,2,6,6-tetramethyl-3,5-heptanedionato)nickel(II))Computed Properties of C22H38NiO4, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(14481-08-4).

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics